ERBB2 and breast carcinoma: However, using array comparative genomic hybridization (aCGH), Dr Sabrina Linn and colleagues from The Netherlands Cancer Institute, Amsterdam, have identified a subset of patients with stage-III, human epidermal growth factor receptor 2 (HER2)-negative BRCA-associated breast cancer who achieve a significantly prolonged survival with high-dose chemotherapy (cyclophosphamide+thiotepa+car boplatin) compared with conventional therapy (fluorouracil+epirubicin+cyclophosphamide [18]).